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ABSTRACT Skin and skin adnexa toxicities are the most common side ef-
fects associated with epidermal growth factor receptor tyrosine kinase in-
hibitors (EGFR-TKIs) and occur in most patients receiving this therapy. The 
majority of these cutaneous side effects are transient, reversible, and dose 
dependent. Although these symptoms are in general not severe, they 
significantly affect quality of life and can have a serious effect on treat-
ment compliance as well as the treatment regimen. The most common 
early symptoms present as papulopustules on an erythematous base, usu-
ally localized in seborrheic areas. This clinical presentation is commonly 
described as “acneiform”, although these adverse reactions have clinical 
presentations, such as rosacea-like and seborrheic-like dermatitis. In this 
context, we report a case of a 77-year-old man with a medical history of 
planocellular lung cancer with ipsilateral pulmonary metastasis and medi-
astinum infiltration who received  erlotinib as a third-line therapy, present-
ing with centrofacial rosaceiform rash as a side effect associated with the 
use of EGFR-TKIs. The patient had a negative previous history of rosacea. 
Therefore, symptoms probably occurred as an adverse reaction due to 
the oncological therapy. Current terminology of early cutaneous adverse 
reactions caused by EGFR-TKIs refers to “acneiform” or “papulopustular” 
lesions, excluding less common side effects such as rosacea-like dermati-
tis  so these symptoms might be overlooked and misdiagnosed. Thus, we 
would like to emphasize the importance of developing a more accurate 
classification of terms in order to provide early detection of all possible cu-
taneous side effects, including less common ones, providing specific and 
timely treatment, and allowing continuation of drug therapy.
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INTRODUCTION
Epidermal growth factor receptor tyrosine ki-
nase inhibitors (EGFR-TKIs) are among the most ex-
tensively used targeted agents for the treatment of 
advanced metastatic tumors such as non-small cell 
lung cancer (NSCLC), breast cancer, and pancreatic 
cancer. The Food and Drug Administration (FDA) has 
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Table 1. Specific skin score for acneiform eruptions 
induced by epidermal growth factor receptor tyro-
sine kinase inhibitors (EGFR-TKIs)
A = Body involvement – 0
B = Facial involvement (extent of lesions on the face, 
0-100%) – 40%
C = Skin lesion score (sum of erythema intensity, 









1/4A + 1/4B + 10/3C = 0 + 40/4 + 7x10/3 = 0 + 10+ 23.3 
= 33.3
approved erlotinib, a small-molecule EGFR-TKI, for 
the treatment of NSCLC and pancreatic cancer. As a 
result of its high specificity it is characterized by low 
systemic toxicities. Although targeted therapies avoid 
common cytotoxic chemotherapy side effects, their 
use is associated with high frequency of cutaneous 
toxicities. The most common cutaneous side effects 
of erlotinib, as well as other epidermal growth factor 
receptor inhibitors (EGFRIs), are skin lesions that are 
commonly classified as “acneiform” or “papulopustu-
lar rash”.
In order to draw attention to other rare clinical 
presentations of these cutaneous adverse reactions 
as well as to discuss the accuracy of their present clas-
sification, we report the case of a male patient who 
developed rosacea-like dermatitis after erlotinib ini-
tiation.
CASE REPORT
A 77-year-old man was referred to our Depart-
ment with a current medical history of planocellular 
lung cancer with ipsilateral pulmonary metastasis 
and mediastinum infiltration. Erlotinib, as a third-line 
therapy, was initiated 17 days prior to our examina-
tion. Seven days after the initiation of erlotinib, the 
patient developed centrofacial rosaceiform rash. The 
patient’s medical history was negative for rosacea 
as well as rhinophyma. Prior to the initiation of erlo-
tinib, he had received four cycles of gemcitabine and 
cisplatin as a first-line chemotherapy for advanced 
NSCLC, and two cycles of docetaxel as a treatment 
for locally advanced or metastatic NSCLC after the 
failure of prior platinum-based chemotherapy. The 
patient presented with disseminated erythematous, 
papular, and dried out pustular lesions, scales, and 
crusts localized in the centrofacial area (Figure 1) with 
an intensive sensation of itching and sensitive skin. 
There were no lesions on the thorax. Additionally, 
the patient presented with fluorescein positive cor-
neal epithelial erosion, which regressed after topical 
antibiotic treatment. The patient’s general condition 
was good, although he had suffered from chronic re-
nal insufficiency and partial respiratory insufficiency. 
Considering the clinical symptoms that were highly 
suggestive of rosaceiform dermatitis, and recent re-
ports suggesting EGFR-TKIs may aggravate rosacea 
or induce rosacea-like symptoms, a biopsy was not 
planned. The patient tested negative for Demodex fol-
Figure 1. Centrofacial rosaceiform rash with dissemi-
nated erythematous papular and dried out pustular 
lesions, scales, and crusts.
Figure 2. Significant regression of centrofacial ery-
thema and papular lesions after use of a fixed combi-
nation of topical corticosteroids and antibiotics (be-
tamethasone, gentamicin) as well as cold compresses 
twice daily for ten days.
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liculorum. A quantification of the adverse reaction of 
all body regions with the specific skin score for acne-
iform eruptions induced by EGFR-TKIs was performed 
(1). The final score was 33.3, indicating moderate 
acneiform eruption (Table 1) (1). Following recent 
guidelines on treatment strategies for EGFR-TKIs side 
effects, a fixed combination of topical corticosteroids 
and antibiotics (betamethasone, gentamicin) as well 
as cold compresses were administered twice daily for 
ten days (2-5). On post-therapeutic follow-up exami-
nation two weeks later, the papular lesions and cen-
trofacial erythema had been significantly diminished, 
as well as the patient’s symptoms of itching and sen-
sitivity (Figure 2). He was prescribed local metronida-
zole and advised to avoid sun exposure, as well as to 
continue use of cold compresses. Two months after-
wards the patient completed the scheduled EGFR-
TKIs therapy and came to our Department for a final 
examination, which showed complete regression of 
all skin lesions (Figure 3). As a result of the quick and 
satisfactory therapeutic effect of the prescribed local 
therapy, there was no need for dose adjustment or 
discontinuation of erlotinib therapy.
DISCUSSION
EGFR-TKIs avoid chemotherapy-related adverse 
effects but are commonly associated with adverse 
skin reactions, which are frequently observed in up 
to 80%-90% of patients receiving targeted treatment 
(4-8). Cutaneous complications of these medications 
develop as a result of the alteration in epidermal dif-
ferentiation and proliferation and hair growth, due 
to the inhibition of the epidermal growth factor re-
ceptor (EGFR), which is expressed in epidermal cells, 
sebaceous glands, and hair follicles (5,6). EGFR is also 
expressed in the basal epithelial cells across the cor-
nea and limbal basal cells where it is considered im-
portant for corneal epithelial cell proliferation and 
wound healing (9). Erlotinib is an oral, highly selective 
tyrosine kinase inhibitor that targets EGFR to inhibit 
tumor cell growth and proliferation (4). It has been 
approved by the FDA for the treatment of NSCLC and 
pancreatic cancer in combination with gemcitabine 
(4). Clinical trials on erlotinib have demonstrated it 
can lead to a variety of skin toxicities that are clas-
sified as early and late cutaneous adverse reactions 
(4-7,10,11). Although the pathophysiological mecha-
nism for the development of these skin disorders is 
not yet fully understood, there is more evidence of 
cutaneous infectious complications in patients using 
EGFR inhibitors, probably due to impairment of the 
epidermal barrier and antimicrobial defense mecha-
nisms that enable the secondary infection to occur 
(2,12,13). Acneiform rash, characterized by papulo-
pustules and usually presenting in seborrheic areas, 
is the earliest common side effect of EGFR-TKIs, ap-
pearing on the 2nd and 3rd week of the treatment in 
45-100% of cases (7,10,11). Although the rash is of-
ten termed “acneiform” or “papulopustular”, these 
skin lesions are pathologically and clinically different 
from acne vulgaris due to the absence of comedo-
nes, the presence of subjective symptoms of itching 
and sensitive skin, and satisfactory response to topi-
cal treatment with metronidazole and high potency 
topical corticosteroids (5,8,14). Furthermore, cases of 
folliculitis and Malassezia sympodialis have also been 
reported as early skin side effects, as well as cases of 
diffuse erythema and telangiectasia (5,13,15-17). Due 
to recent data showing increased density of Demodex 
folliculorum in the skin of the patients receiving EG-
FRIs, some researchers have also suggested introduc-
ing a new term, “rosacea-like” or “rosaceiform” derma-
titis (14). Since grading and classification of these skin 
lesions have mostly been done by oncologists, the 
term “acneiform rash” or “papulopustular rash” covers 
a broad spectrum of different clinical presentations 
including pustular, papular, pruritic, erythematous, 
or generalized rash, acneiform exfoliative dermati-
tis, and dry skin (8,12). Due to these different clinical 
presentations that can mimic other dermatological 
conditions and the current classification that has not 
proven to be accurate enough, differential diagnosis 
can be truly challenging (5). Due to the importance 
and necessity of accurate grading of early EGFR inhib-
itor cutaneous adverse events, several grading scales 
Figure 3. Complete regression of skin lesions after 
discontinuation of erlotinib.
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have had been developed, including the National 
Cancer Institute’s Common Terminology Criteria for 
Adverse Events version 4.0 (NCI-CTCAE v4.0) as the 
most widely used one, and the Multinational Associa-
tion of Supportive Care in Cancer (MASCC) Skin Toxic-
ity Study Group which was developed specifically for 
these targeted agents, resulting in improved sensitiv-
ity and specificity (2,5-7,11). Nevertheless, these grad-
ing scales also have limitations and deficiencies be-
cause they imply “acneiform” or “papulopustular” rash 
is the only clinical presentation of these early cuta-
neous adverse reactions. Furthermore, there are also 
late cutaneous adverse reactions usually developing 
several weeks after the initiation of EGFR tyrosine 
kinase inhibitor treatment including xerosis, skin fis-
sures, alterations in hair growth, hyperpigmentation, 
and telangiectasia (5,6,8,11,18). Nail disorders includ-
ing paronychia, periungual abscesses, and pyogenic 
granuloma may also develop (5,8). Although the 
clinical presentation of cutaneous adverse reactions 
of EGFR-TKIs is moderate in the majority of cases, if 
left untreated it can affect the patient’s quality of life 
(QoL), leading to stigmatization and a large psycho-
logical burden as well as interfering with treatment 
compliance, leading to drug reduction or discontinu-
ation of the treatment (4-7,18). We report this case in 
order to draw attention to rosacea-like dermatitis as 
a possible cutaneous adverse reaction of EGFR-TKIs, 
emphasizing the need for more accurate classifica-
tion of these side effects that are presently classified 
as “acneiform” or “papulopustular” lesions, despite the 
fact that the side effect can have a number of quite 
different clinical patterns.
CONCLUSION
The term “acneiform rash” or “papulopustular rash” 
does not sufficiently illustrate other clinical forms that 
are not as common, but are nevertheless also associ-
ated with EGFR-TKIs. The great heterogeneity in the 
definitions of these skin toxicities must be acknowl-
edged, as they are reported differently in research 
and trials. Accordingly, their accurate classification is 
of crucial importance in order to provide early detec-
tion and timely treatment, enabling continuation of 
EGFR –TKI treatment without any alterations.
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